Ziyuglycoside IICAS# 35286-59-0 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 35286-59-0 | SDF | Download SDF |
| PubChem ID | 71773126 | Appearance | Powder |
| Formula | C35H56O8 | M.Wt | 604.8 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Synonyms | Gouguside 1; Pomolic acid 3-arabinoside; Zigu-glucoside II | ||
| Solubility | Soluble in DMSO and methanol; insoluble in water | ||
| Chemical Name | (1R,2R,4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-1-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-10-[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxy-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid | ||
| SMILES | CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C)OC6C(C(C(CO6)O)O)O)C)C)C2C1(C)O)C)C(=O)O | ||
| Standard InChIKey | MFIXLWYJTVEVGO-YHGWSDCJSA-N | ||
| Standard InChI | InChI=1S/C35H56O8/c1-19-10-15-35(29(39)40)17-16-32(5)20(27(35)34(19,7)41)8-9-23-31(4)13-12-24(30(2,3)22(31)11-14-33(23,32)6)43-28-26(38)25(37)21(36)18-42-28/h8,19,21-28,36-38,41H,9-18H2,1-7H3,(H,39,40)/t19-,21+,22+,23-,24+,25+,26-,27-,28+,31+,32-,33-,34-,35+/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Ziyuglycoside II has a wide range of clinical applications including hemostasis, antibiosis, anti-inflammation and anti-oxidation. Ziyuglycoside II has inhibitory effect on the growth of MDA-MB-435 cells, it induces cell cycle arrest and apoptosis through activation of ROS/JNK pathway in human breast cancer cells.Ziyuglycoside II methyl ester possess improved anti-diabetic properties, and has hepato-renal protective activities in type 2 diabetes. |
| Targets | ROS | JNK | p21 | Bcl-2/Bax | Caspase | p53 |
| In vitro | Ziyuglycoside II induces cell cycle arrest and apoptosis through activation of ROS/JNK pathway in human breast cancer cells.[Pubmed: 24680927]Toxicol Lett. 2014 May 16;227(1):65-73.Ziyuglycoside II, a triterpenoid saponin compound extracted from Sanguisorba officinalis L., has been reported to have a wide range of clinical applications including anti-cancer effect. In this study, the anti-proliferative effect of Ziyuglycoside II in two classic human breast cancer cell lines, MCF-7 and MDA-MB-231, was extensively investigated.
|
| In vivo | Anti-Diabetic and Hepato-Renal Protective Effects of Ziyuglycoside II Methyl Ester in Type 2 Diabetic Mice.[Pubmed: 26198246]Nutrients. 2015 Jul 7;7(7):5469-83.Type 2 diabetes is a metabolic disorder caused by abnormal carbohydrate metabolism, and closely associated with abnormal lipid metabolism and hepato-renal dysfunction.
This study investigated the anti-diabetic and hepato-renal protective properties of ziyuglycoside I (ZG01) derivative on type 2 diabetes.
|
| Cell Research | Ziyuglycoside II-induced apoptosis in human gastric carcinoma BGC-823 cells by regulating Bax/Bcl-2 expression and activating caspase-3 pathway.[Pubmed: 23969976]Braz J Med Biol Res. 2013 Aug;46(8):670-5.Ziyuglycoside II is an active compound of Sanguisorba officinalis L. that has anti-inflammation, antioxidation, antibiosis, and homeostasis properties. We report here on the anticancer effect of Ziyuglycoside II on human gastric carcinoma BGC-823 cells.
|
| Structure Identification | J Sep Sci. 2015 Apr 17.Development and validation of a quantification method for ziyuglycoside I and II in rat plasma: Application to their pharmacokinetic studies.[Pubmed: 25885584]This study provided a novel and generally applicable method to determine ziyuglycoside I and Ziyuglycoside II in rat plasma based on liquid chromatography with tandem mass spectrometry.
|
Ziyuglycoside II Dilution Calculator
Ziyuglycoside II Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.6534 mL | 8.2672 mL | 16.5344 mL | 33.0688 mL | 41.336 mL |
| 5 mM | 0.3307 mL | 1.6534 mL | 3.3069 mL | 6.6138 mL | 8.2672 mL |
| 10 mM | 0.1653 mL | 0.8267 mL | 1.6534 mL | 3.3069 mL | 4.1336 mL |
| 50 mM | 0.0331 mL | 0.1653 mL | 0.3307 mL | 0.6614 mL | 0.8267 mL |
| 100 mM | 0.0165 mL | 0.0827 mL | 0.1653 mL | 0.3307 mL | 0.4134 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Ziyuglycoside I
Catalog No.:BCN5290
CAS No.:35286-58-9
- 1-Chloroindan
Catalog No.:BCN2244
CAS No.:35275-62-8
- Caesalmin B
Catalog No.:BCN7252
CAS No.:352658-23-2
- Delafloxacin meglumine
Catalog No.:BCC1523
CAS No.:352458-37-8
- 9-Methoxy-alpha-lapachone
Catalog No.:BCN5289
CAS No.:35241-80-6
- Benzoin methyl ether
Catalog No.:BCC8857
CAS No.:3524-62-7
- 4-(Bromomethyl)-7-methoxy coumarin
Catalog No.:BCC9202
CAS No.:35231-44-8
- Alloisoimperatorin
Catalog No.:BCN6789
CAS No.:35214-83-6
- Neobyakangelicol
Catalog No.:BCN5288
CAS No.:35214-82-5
- Ipriflavone (Osteofix)
Catalog No.:BCC5323
CAS No.:35212-22-7
- 4,5-Dimethoxy-1-cyanobenzocyclobutane
Catalog No.:BCC8665
CAS No.:35202-54-1
- AY-NH2
Catalog No.:BCC3949
CAS No.:352017-71-1
- (E)-3-Hydroxy-5-methoxystilbene
Catalog No.:BCN5292
CAS No.:35302-70-6
- D-Alaninol
Catalog No.:BCC2728
CAS No.:35320-23-1
- LY 487379 hydrochloride
Catalog No.:BCC7627
CAS No.:353229-59-1
- NS 6180
Catalog No.:BCC6307
CAS No.:353262-04-1
- S26948
Catalog No.:BCC7751
CAS No.:353280-43-0
- Monocrotaline N-oxide
Catalog No.:BCN2097
CAS No.:35337-98-5
- TQS
Catalog No.:BCC7896
CAS No.:353483-92-8
- 9-Hydroxycalabaxanthone
Catalog No.:BCN5293
CAS No.:35349-68-9
- HLM006474
Catalog No.:BCC5403
CAS No.:353519-63-8
- Honokiol
Catalog No.:BCN1001
CAS No.:35354-74-6
- J 113863
Catalog No.:BCC7422
CAS No.:353791-85-2
- Norathyriol
Catalog No.:BCN5294
CAS No.:3542-72-1
Development and validation of a quantification method for ziyuglycoside I and II in rat plasma: Application to their pharmacokinetic studies.[Pubmed:25885584]
J Sep Sci. 2015 Jul;38(13):2340-7.
This study provided a novel and generally applicable method to determine ziyuglycoside I and Ziyuglycoside II in rat plasma based on liquid chromatography with tandem mass spectrometry. A single step of liquid-liquid extraction with n-butanol was utilized, and ginsenoside Rg3 was chosen as internal standard. Final extracts were analyzed based on liquid chromatography with tandem mass spectrometry. Chromatographic separation was achieved using a Thermo Golden C18 column, and the applied gradient elution program allowed for the simultaneous determination of two ziyuglycosides in a one-step chromatographic separation with a total run time of 10 min. The fully validated methodology for both analytes demonstrated high sensitivity (the lower limit of quantitation was 2.0 ng/mL), good accuracy (% RE Ziyuglycoside II. The presently developed methodology would be useful for the preclinical and clinical pharmacokinetic studies for ziyuglycoside I and Ziyuglycoside II.
Ziyuglycoside II inhibits the growth of human breast carcinoma MDA-MB-435 cells via cell cycle arrest and induction of apoptosis through the mitochondria dependent pathway.[Pubmed:24005866]
Int J Mol Sci. 2013 Sep 3;14(9):18041-55.
Ziyuglycoside II is one of the major active compounds of Sanguisorba officinalis L., which has a wide range of clinical applications including hemostasis, antibiosis, anti-inflammation and anti-oxidation. This study investigated the effect of Ziyuglycoside II on the growth of human breast carcinoma MDA-MB-435 cells for the first time. The results showed that Ziyuglycoside II could significantly inhibit the growth of MDA-MB-435 cells through blocking cell cycle progression at G0/G1 and S phase as well as via inducing cell apoptosis. Accumulation of reactive oxygen species (ROS) was observed in the progression of cell cycle arrest, which was associated with the increased expression of cell cycle regulating factors, p53 and p21. Subsequent apoptosis induced by Ziyuglycoside II was accompanied with the activation of mitochondrial pathway, in particular a decreased mitochondrial membrane potential (MMP) as well as increased Bax/Bcl-2 ratio, cytochrome c release and the activity of caspase-3 and caspase-9. In conclusion, our study was the first to report that Ziyuglycoside II has inhibitory effect on the growth of MDA-MB-435 cells, which might become a potential therapeutic approach of breast cancer in the future.
Anti-Diabetic and Hepato-Renal Protective Effects of Ziyuglycoside II Methyl Ester in Type 2 Diabetic Mice.[Pubmed:26198246]
Nutrients. 2015 Jul 7;7(7):5469-83.
Type 2 diabetes is a metabolic disorder caused by abnormal carbohydrate metabolism, and closely associated with abnormal lipid metabolism and hepato-renal dysfunction. This study investigated the anti-diabetic and hepato-renal protective properties of ziyuglycoside I (ZG01) derivative on type 2 diabetes. ZG01 was isolated from roots of Sanguisorba officinalis and chemically modified by deglycosylation and esterification to obtained Ziyuglycoside II methyl ester (ZG02-ME). Here, we showed that ZG02-ME has stronger anti-diabetic activity than the original compound (ZG01) through decreasing blood glucose, glycated hemoglobin (HbA1c), and insulin levels in a mouse model of type 2 diabetes (db/db mice). We further found that ZG02-ME treatment effectively ameliorated serum insulin, leptin and C-peptide levels, which are key metabolic hormones, in db/db mice. In addition, we showed that elevated basal blood lipid levels were decreased by ZG02-ME treatment in db/db mice. Furthermore, treatment of ZG02-ME significantly decreased serum AST, ALT, BUN, creatinine, and liver lipid peroxidation in db/db mice. These results demonstrated that compared to ZG01, chemically modified ZG02-ME possess improved anti-diabetic properties, and has hepato-renal protective activities in type 2 diabetes.
Ziyuglycoside II induces cell cycle arrest and apoptosis through activation of ROS/JNK pathway in human breast cancer cells.[Pubmed:24680927]
Toxicol Lett. 2014 May 16;227(1):65-73.
Ziyuglycoside II, a triterpenoid saponin compound extracted from Sanguisorba officinalis L., has been reported to have a wide range of clinical applications including anti-cancer effect. In this study, the anti-proliferative effect of Ziyuglycoside II in two classic human breast cancer cell lines, MCF-7 and MDA-MB-231, was extensively investigated. Our study indicated that Ziyuglycoside II could effectively induce G2/M phase arrest and apoptosis in both cell lines. Cell cycle blocking was associated with the down-regulation of Cdc25C, Cdc2, cyclin A and cyclin B1 as well as the up-regulation of p21/WAF1, phospho-Cdc25C and phospho-Cdc2. Ziyuglycoside II treatment also induced reactive oxygen species (ROS) production and apoptosis by activating the extrinsic/Fas/FasL pathway as well as the intrinsic/mitochondrial pathway. More importantly, the c-Jun NH2-terminal kinase (JNK), a downstream target of ROS, was found to be a critical mediator of Ziyuglycoside II-induced cell apoptosis. Further knockdown of JNK by siRNA could inhibit Ziyuglycoside II-mediated apoptosis with attenuating the up-regulation of Bax and Fas/FasL as well as the down-regulation of Bcl-2. Taken together, the cell death of breast cancer cells in response to Ziyuglycoside II was dependent upon cell cycle arrest and cell apoptosis via a ROS-dependent JNK activation pathway. Our findings may significantly contribute to the understanding of the anti-proliferative effect of Ziyuglycoside II, in particular to breast carcinoma and provide novel insights into the potential application of such compound in breast cancer therapy.
Ziyuglycoside II-induced apoptosis in human gastric carcinoma BGC-823 cells by regulating Bax/Bcl-2 expression and activating caspase-3 pathway.[Pubmed:23969976]
Braz J Med Biol Res. 2013 Aug;46(8):670-5.
Ziyuglycoside II is an active compound of Sanguisorba officinalis L. that has anti-inflammation, antioxidation, antibiosis, and homeostasis properties. We report here on the anticancer effect of Ziyuglycoside II on human gastric carcinoma BGC-823 cells. We investigated the effects of Ziyuglycoside II on cell growth, cell cycle, and cell apoptosis of this cell line. Our results revealed that Ziyuglycoside II could inhibit the proliferation of BGC-823 cells by inducing apoptosis but not cell cycle arrest, which was associated with regulation of Bax/Bcl-2 expression, and activation of the caspase-3 pathway. Our study is the first to report the antitumor potential of Ziyuglycoside II in BGC-823 gastric cancer cells. Ziyuglycoside II may become a potential therapeutic agent against gastric cancer in the future.
